- Home
- STGW vs AUPH Comparison
STGW vs AUPH Comparison
Compare STGW & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STGW | AUPH |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | STGW | AUPH |
|---|---|---|
| Price | $6.22 | $14.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $8.46 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.1M | 998.7K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1954.71 | N/A |
| EPS | 0.06 | ★ 0.55 |
| Revenue | ★ $2,890,264,000.00 | $265,808,000.00 |
| Revenue This Year | $4.67 | $21.76 |
| Revenue Next Year | $8.98 | $16.45 |
| P/E Ratio | $112.85 | ★ $26.74 |
| Revenue Growth | 6.75 | ★ 20.62 |
| 52 Week Low | $4.03 | $6.55 |
| 52 Week High | $7.48 | $16.54 |
Technical Indicators
Market Signals| Indicator | STGW | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 39.65 |
| Support Level | $4.80 | $14.36 |
| Resistance Level | $7.17 | $15.19 |
| Average True Range (ATR) | 0.43 | 0.49 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 60.47 | 13.94 |
Price Performance
Historical ComparisonAbout STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.